13.07.2018
Biofrontera AG DE0006046113
DGAP-News: Biofrontera AG: Biofrontera AG announces results of its Annual General Meeting
DGAP-News: Biofrontera AG / Key word(s): AGM/EGM
Biofrontera AG: Biofrontera AG announces results of its Annual General
Meeting
13.07.2018 / 10:40
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Biofrontera AG announces results of its Annual General Meeting
Leverkusen, Germany, July 13, 2018 -Biofrontera AG (NASDAQ: BFRA; Frankfurt
Stock Exchange: B8F), an international biopharmaceutical company, today
announced the voting results of its annual general meeting of shareholders
(the "Meeting") held on July 11, 2018. Shareholders representing 62,86% of
the company's registered share capital attended the Meeting.
The shareholders voted overwhelmingly in favor of all agenda items 2-5 of
the company, as published in the German Federal Gazette on June 4, 2018,
including the election of Mr. Eyring as a new member of the Supervisory
Board. The shareholders, with a clear majority, rejected the additional
agenda items 7-20 previously submitted by Deutsche Balaton AG. No vote was
required on agenda items 1 and 6.
"I would like to thank our shareholders for their continued support and
continuous trust," said Dr. Ulrich Granzer, Chairman of the Supervisory
Board of Biofrontera AG, who chaired the Meeting. "On behalf of the
Supervisory Board, I would like to congratulate Mr. Eyring on his election
to our Board and look forward to working with him."
In their presentations, the Management Board members emphasized the
successes on the regulatory side, the increasing product sales in Europe and
the US as well as the improved visibility of the company in the US following
its IPO on NASDAQ. "We have set ourselves the goal of rapidly growing the
market potential of Ameluz(R) and our strategy of expanding the indications
for Ameluz(R) is already showing initial success. The recent approval for
daylight PDT in Europe as well as the US billing codes released in January
now allow patients with actinic keratoses broad access to Ameluz(R)," said
CEO Prof. Dr. Hermann Lübbert.
The company has published a detailed report of the voting results on its
website at www.biofrontera.com.
-End-
For enquiries, please contact: +49 (0) 214 87 63 2 0
[email protected]
Biofrontera AG
Thomas Schaffer, Chief Financial Officer
IR UK: Seton Services +44(0) 20 7224 8468
Toni Vallen
IR and PR US: The Ruth Group +1 646-536-7035
IR: Tram Bui +1 508-280-6592
PR: Kirsten Thomas
About Biofrontera:
Biofrontera AG is an international biopharmaceutical company specializing in
the development and commercialization of a platform of pharmaceutical
products for the treatment of dermatological conditions and diseases caused
primarily by exposure to sunlight that results in sun damage to the skin.
Biofrontera's approved products focus on the treatment in the U.S. and
Europe of actinic keratoses, which are skin lesions that can sometimes lead
to skin cancer, as well as the treatment of certain forms of basal cell
carcinoma in the European Union. American Depositary Shares representing
Biofrontera's ordinary shares are listed on the NASDAQ Capital Market under
the symbol "BFRA", and Biofrontera's ordinary shares are listed in the
Frankfurt Stock Exchange (B8F, ISIN: DE0006046113). Information is also
available at www.biofrontera.com.
Forward Looking Statements:
Certain statements in this press release are forward-looking within the
meaning of the Private Securities Litigation Reform Act of 1995 regarding
the public offering and the intended use of proceeds from the offering.
These statements may be identified by the use of forward-looking words such
as "anticipate," "believe," "forecast," "estimate" and "intend," among
others. Such forward-looking statements are based on the currently held
beliefs and assumptions of the management of Biofrontera AG, which are
expressed in good faith and, in their opinion, reasonable. Forward-looking
statements involve known and unknown risks, uncertainties and other factors,
which may cause the actual results, financial condition, performance, or
achievements of the Company, or industry results, to differ materially from
the results, financial condition, performance or achievements expressed or
implied by such forward-looking statements. These risks, uncertainties and
other factors are set forth in the Registration Statement on Form F-1 filed
with the SEC, including in the section "Risk Factors," and in future reports
that we will file with the SEC. Given these risks, uncertainties and other
factors, prospective investors are cautioned not to place undue reliance on
these forward-looking statements. The Company does not undertake an
obligation to update or revise any forward-looking statement.
---------------------------------------------------------------------------
13.07.2018 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: [email protected]
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime
Standard); Regulated Unofficial Market in Berlin, Hamburg,
Munich, Stuttgart, Tradegate Exchange; Nasdaq
End of News DGAP News Service
---------------------------------------------------------------------------
704375 13.07.2018
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Biofrontera AG ISIN: DE0006046113 können Sie bei EQS abrufen
Biotechnologie , 604611 , B8F , XETR:B8F